News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
byAudrey Abella
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
13 Feb 2024

Intensive lifestyle intervention reduces long-term variability in blood sugar, lipids
11 Feb 2024
byJairia Dela Cruz
For people with overweight or obesity and type 2 diabetes, intensive lifestyle intervention appears to minimize the spikes and drops in cardiovascular risk factors such as blood glucose and lipids.
11 Feb 2024






